Sydney, Australia 20 April 2018 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it was invited to give oral presentations and presentations of their posters at the upcoming 12th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB) in Melbourne.
Clarity’s CEO, Dr Matthew Harris, will give an invited oral presentation on “User Experiences, Practicalities and Business Models for Start-ups – The Clarity Pharmaceuticals Journey” on Tuesday, 24th of April, at 4:15pm. He will also be one of the speakers at the industry program, sharing his insights on the Next Generation Theranostics on Saturday, 21st of April, at 7:00am.
Clarity’s Head of Quality, Dr Colin Biggin, will be presenting the poster entitled “Initial standardisation of Next Generation Theranostics: Preparation for clinical trials with Cu-64 SARTATE”.
Clarity’s radiochemist, Charmaine Jeffery, will be presenting the poster entitled “Centralised manufacture of 64Cu-SARTATE for clinical trials”.
There are also two posters that will be presented by Clarity’s collaborators. One of them is Jon Stoner from the Idaho Accelerator Center (IAC) at Idaho State University, presenting a poster entitled “Production of High Specific Activity e- LINAC Produced 67Cu for use in radionuclide therapy”. The second poster is presented by Kathy Willowson from the University of Sydney. The poster is entitled “Experimental work up and validation of 67Cu quantitative SPECT”.
About Clarity
Clarity Pharmaceuticals is a personalised medicine company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceutical technology, developing targeted therapies and assisting in the drug development pipeline of novel therapies for companies globally.
www.claritypharmaceuticals.com
Media Contact
Dr Alan Taylor
Executive Chairman
Ph: +61 (0)413 871 165
E: ataylor@claritypharm.com
